Armstrong Quoted On Changes To Specialty Pharma Industry In 2010Specialty Pharma News December 15, 2009
Mark Armstrong, a Member of the Firm in the Health Care and Life Sciences practice of Epstein Becker Green Wickliff & Hall in Houston, was quoted in two articles on the impact of health reform on the specialty pharma industry, in Specialty Pharma News, December 2010.
An article titled "Reform Could Offer Challenges, Opportunities for Specialty Firms," stated that the creation of an approval pathway for biosimilars may be the most prominent health reform issue for the specialty pharmacy industry. Armstrong remarked that estimates of $10 billion in savings over 10 years is one reason that a biosimilar provision in any health reform bill is "likely."
A second article, "CAP, Home Infusion Coverage Gap May Not See Action Next Year," reported that skepticism exists about the chances of a restart of the Medicare Part B Competitive Acquisition Program (CAP) and closure of the Medicare home infusion coverage gap.
Armstrong said it seems that Congress understands this issue of the coverage gap, but added: "I am uncertain if a solution can be reached and incorporated into 2010 legislation."